Article

Two-year data promising for dual-optic accommodating IOL

The newer generation of a dual-optic accommodating IOL (Synchrony, Visiogen) is easy to implant, centers well, provides good distance visual acuity, and demonstrates good safety in terms of potential posterior capsule opacification development, according to H. Burkhard Dick, MD.

The newer generation of a dual-optic accommodating IOL (Synchrony, Visiogen) is easy to implant, centers well, provides gooddistance visual acuity, and demonstrates good safety in terms of potential posterior capsule opacification development,according to H. Burkhard Dick, MD.

Dr. Dick, professor of ophthalmology, Johannes-Gutenberg University, Mainz, Germany, discussed 2-year data related to hisexperience of implanting 30 of the silicone lenses, which have a high diopter anterior optic and a minus power posterioroptic, in a prospective trial of otherwise healthy eyes.

"The most important thing was preoperative counseling and biometrics," he said. "This included lens thickness evaluation."

Focus curve measurement showed that the IOL demonstrated accommodative amplitude in every patient, even after 2 years, Dr.Dick said. The mean was 1.5 to 1.75 D. Also, he said, no Nd:YAG capsulotomies have been required.

"All patients were very satisfied with the lens, and in terms of functionality, it was quite satisfying. Also, reading speedwas very sufficient," Dr. Dick said.

Because of its relatively large size, the IOL requires a relatively large incision for implantation, he said.

"My standard incision size is about 2.75 mm, but this is a thickness [where] you can't implant this lens," Dr. Dick said.

The lens has earned a CE Mark in Europe, he added.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
© 2025 MJH Life Sciences

All rights reserved.